This small-cap Stock, engaged in manufacturing, marketing, and exporting pharmaceutical products, with a focus on research in Oncology, Immunology, and Anti-infectives across global markets, jumped 12 percent after the company reported March quarterly results with a 159.36 percent QOQ increase in net profit and announced a total dividend of Rs. 165 per equity share.
With a market capitalization of Rs. 22,632.32 crores, the share of Pfizer Limited has reached an intraday high of Rs. 4,995.85 per equity share, rising nearly 11.90 percent from its previous day’s close price of Rs. 4,464.25. Since then, the stock has retreated and is currently trading at Rs. 4,947.20 per equity share.
Q4 FY25 Result Walkthrough
Coming into the quarterly results of Pfizer Limited, the company’s consolidated revenue from operations increased by 8.28 percent YOY, from Rs. 546.63 crore in Q4 FY24 to Rs. 591.91 crore in Q4 FY25, and grew by 10.02 percent QoQ from Rs. 537.99 crore in Q3 FY25.
In Q4 FY25, Pfizer Limited’s consolidated net profit increased by 85.03 percent YOY, reaching Rs. 330.94 crore compared to Rs. 178.86 crore during the same period last year.
This surged due to the transfer of Pfizer’s leasehold rights and the sale of buildings on MIDC land in Thane to Zoetis for Rs. 264.40 crore, completing the transaction by March 2025 with a net gain of Rs. 172.81 crore. As compared to Q3 FY25, the net profit has increased by 159.36 percent, from Rs. 127.60 crore. The basic earnings per share increased by 85.06 percent and stood at Rs. 72.34 as against Rs. 39.09 recorded in the same quarter in the previous year, 2024.
Dividend: The Pfizer board of directors has recommended paying a total dividend at the rate of 1650 percent on the face value of paid-up equity shares of Rs. 10 each for the financial year 2024-25, which is a total dividend of Rs. 165 per equity share.
This includes a final dividend of Rs. 35 per share, a special Rs. 100 dividend to mark Pfizer’s 75th year in India, and another special Rs. 30 dividend from the profit on transferring leasehold land and its building. The date of payment of the dividend shall be 9 July 2025.
FY25 Result: Pfizer Limited’s revenue has increased from Rs. 2,193.17 crore in FY24 to Rs. 2,281.35 crore in FY25, which is a growth of 4.02 percent. The net profit has also grown by 39.23 percent, from Rs. 551.33 crore in FY24 to Rs. 767.60 crore in FY25.
Pfizer Limited was established in 1950 and is a leading Indian pharmaceutical company and subsidiary of Pfizer Inc. Headquartered in Mumbai, it manufactures and markets a wide range of medicines and vaccines. Pfizer Limited is known for its innovation, strong brand portfolio, and commitment to improving health in India.
Pfizer Limited operates three manufacturing facilities with a total annual capacity of 4.5 billion units. The company also has two research and development centers and six regional centers supporting commercial and global operations.
As the fourth-largest multinational pharmaceutical company in India by revenue, Pfizer offers products across over 16 therapies, exports to over 50 countries, and focuses research in Oncology, Immunology, and Anti-infectives.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
